Clinical Supply, Gene, Life Science and Protein

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Clinical Supply

Gene

Life Science

Protein

J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma

XTalks

APRIL 11, 2024

Moreover, rather than producing antibodies, the cancer cells produce abnormal proteins that can cause complications. The companies have also expanded a contract manufacturing agreement with Novartis that will help produce Carvykti for both commercial and clinical supply at the New Jersey plant through the end of 2029.

FDA Approval

FDA Approval Manufacturing Trials Clinical Trials

VTX-801 RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF WILSON DISEASE

The Pharma Data

AUGUST 15, 2021

Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease.

Gene Therapy

Gene Therapy Gene Clinical Trials Clinical Trials

Clinical Research Informer

J&J’s Carvykti and BMS’ Abecma Win FDA Approvals for Earlier Use in Multiple Myeloma

VTX-801 RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF WILSON DISEASE

Stay Connected